Durata Therapeutics, Inc. reports that the U.S. Food and Drug Administration has approved DALVANCE™ (dalbavancin) for injection for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA).
DALVANCE™ is the first and only IV antibiotic approved for the treatment of ABSSSI with a two-dose regimen of 1000 mg followed one week later by 500 mg, each administered over 30 minutes.
— UPCOMING EVENTS —
6/5 4:00 pm – 6:00 pm in New Haven
CURE annual meeting and BioHaven panel discussion: “Growing Connecticut’s Bioscience Community: Supporting Ideas, Creating Value” … more
6/16 4:30 pm – 6:00 pm in Farmington
BioScienceClubhouseCT presents ‘CORNOVUS Pharmaceuticals: Novel Treatment for Heart Failure’ … more